Saxagliptin
Saxagliptin, a wɔtɔn no wɔ edin Onglyza ase no, yɛ aduro a wɔde di dwuma a ɛma mogya mu sukyerɛmma so te (anti-diabetic drug) a ɛwɔ dipeptidyl peptidase-4 (DPP-4) inhibitor class mu[1][2]. Bristol-Myers Squibb nkutoo na wɔyɛɛ no; wɔ afe 2007 mu no AstraZeneca ne Bristol-Myers Squibb boom yɛɛ aduru a etwa to no, na wɔboom yɛɛ no ho adwuma de too dwa.
Baabi a menyaa mmoa firiiɛ
sesa- ↑ David J. Augeri, Jeffrey A. Robl, David A. Betebenner, David R. Magnin, Ashish Khanna, James G. Robertson, Aiying Wang, Ligaya M. Simpkins, Prakash Taunk, Qi Huang, Song-Ping Han, Benoni Abboa-Offei, Michael Cap, Li Xin, Li Tao, Effie Tozzo, Gustav E. Welzel, Donald M. Egan, Jovita Marcinkeviciene, Shu Y. Chang, Scott A. Biller, Mark S. Kirby, Rex A. Parker, Lawrence G. Hamann (2005-07-01), "Discovery and Preclinical Profile of Saxagliptin (BMS-477118): A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes", Journal of Medicinal Chemistry (in English), vol. 48, no. 15, pp. 5025–5037, doi:10.1021/jm050261p, ISSN 0022-2623, retrieved 2024-08-26
{{citation}}: CS1 maint: multiple names: authors list (link) - ↑ Politics - Bloomberg (in English), retrieved 2024-08-26